Recently, the lowest average wholesale price of 200 milligram Celebrex and the price of multiple strengths of Abilify dropped dramatically, resulting in major cost savings to Medicare set-aside allocations.
A widely used, non-steroidal anti-inflammatory drug, Celebrex (Celecoxib), is FDA-approved for several conditions:
Per Red Book, the lowest average wholesale price for 200 milligram Celecoxib dropped from $1.79 to $0.33, an 81.56% reduction.
Abilify (Aripiprazole) is an antipsychotic drug FDA-approved for the following conditions:
Per Red Book, the lowest average wholesale price for multiple strengths (2 milligrams to 30 milligrams) of Aripiprazole dropped from the $30 to $36 range to a range of $0.07 to $0.17 per dose, an almost 100% price reduction.
Because Tower’s system tracks all medications allocated in MSA reports, we have already pulled reports from the past two years that allocated these medications and advised clients of the potential for a reduction. You can also contact us to determine whether a particular MSA qualifies for a reduction. Revisions to the MSA can be done now or prior to MSA submission to the Centers for Medicare and Medicaid.
Dan Anders is chief compliance officer at Tower MSA Partners LLC. This entry is republished with permission from the Tower MSP Compliance Blog.
May 5-8, 2024
Amplify Your Impact There’s no limit to what you can achieve when you join the global risk managem …
May 13-15, 2024
Join us May 13–15, 2024, for NCCI's Annual Insights Symposium (AIS) 2024, the industry’s premier e …
May 13-14, 2024
The Board of Managers is excited to announce that the CSIA 2024 Annual Meeting and Educational Con …
No Comments
Log in to post a comment